Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.

By C. Shults, D. Oakes, K. Kieburtz, M. Beal, R. Haas, M. Chir, Sandra Plumb, J. Juncos, J. Nutt, I. Shoulson and 10 more. Archives of Neurology, 2002

1,036 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/26f20b33facc9d71d2913983ca7664b5380ba63c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Todd B. Sherer
2. Claudia M. Testa
3. R. Betarbet
4. B. Seo
5. J. Richardson
6. J. Greenamyre
7. Jin Hoo Kim
8. Gary W. Miller

Citations in the corpus

• The Role of Oxidative Stress in Neurodegenerative Diseases (2015, methodology): “A summary of clinical studies for neurodegenerative diseases is presented in Table 1 [121-137].”
• Mechanism of Toxicity in Rotenone Models of Parkinson's Disease (2003, background): “Recently, a small, randomized, placebocontrolled, double-blind study suggested that coenzyme Q10 may slow PD progression (Shults et al., 2002).”
• Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. (2010, unknown): “In clinical trials, CoQ 10 treatment showed a trend toward slowing functional decline in both Huntington and Parkinson disease patients (at doses of 600 and up to 1200 mg/day, respectively) [225] [226] [227] .”